Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,399,328 papers from all fields of science
Search
Sign In
Create Free Account
GART wt Allele
Known as:
PGFT
, GARFT
, AIRS
Expand
Human GART wild-type allele is located in the vicinity of 21q22.11 and is approximately 40 kb in length. This allele, which encodes trifunctional…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
21q22.11
Anabolism
GART gene
Nucleotide Biosynthesis
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
R. Zhao
,
Shubing Zhang
,
M. Hanscom
,
S. Chattopadhyay
,
I. Goldman
Clinical Cancer Research
2005
Corpus ID: 24934789
Pemetrexed is a novel antifolate with polyglutamate derivatives that are potent inhibitors of thymidylate synthase (TS) and to a…
Expand
Highly Cited
2004
Highly Cited
2004
AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase
T. Boritzki
,
C. Barlett
,
+5 authors
R. Jackson
Investigational new drugs
2004
Corpus ID: 5687386
SummaryThe glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5…
Expand
2004
2004
A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid
S. Laohavinij
,
S. Wedge
,
+13 authors
A. Calvert
Investigational new drugs
2004
Corpus ID: 23915783
SummaryLometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for…
Expand
2004
2004
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol
L. G. Mendelsohn
,
C. Shih
,
R. Schultz
,
J. Worzalla
Investigational new drugs
2004
Corpus ID: 22723118
SummaryLometrexol, a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase…
Expand
2001
2001
Efectividad de los programas de mantenimiento con metadona. Una revisión de los resultados de los estudios de evaluación
J. Miranda
2001
Corpus ID: 72008913
Review
1999
Review
1999
Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887
L. G. Mendelsohn
,
J. Worzalla
,
J. Walling
1999
Corpus ID: 68247657
The importance of the purine de novo pathway in providing DNA precursors for cancer cell growth led to the hypothesis that novel…
Expand
1997
1997
An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint
Cathy C. Zhang
,
T. Boritzki
,
R. Jackson
Cancer Chemotherapy and Pharmacology
1997
Corpus ID: 13421876
Purpose: We studied the effects of purine depletion on the cell cycle using a specific inhibitor of de novo purine biosynthesis…
Expand
1997
1997
Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
S. Sanghani
,
R. Moran
Biochemistry
1997
Corpus ID: 23152494
The binding of the prototypical folate inhibitor of de novo purine synthesis, 5,10-dideazatetrahydrofolate (DDATHF), and its…
Expand
1997
1997
Un sistema de clasificación de pacientes para nuestra atención primaria: los ambulatory care groups (ACGs)
S. Juncosa
,
B. Bolíbar
1997
Corpus ID: 72839732
1992
1992
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
A. Rosowsky
,
J. Galivan
,
+7 authors
J. Freisheim
Cancer Research
1992
Corpus ID: 8507259
Biochemical and biological studies have been carried out with 2-desamino-2-methylaminopterin (dmAMT), which inhibits tumor cell…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE